Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2020

01-09-2020 | Hepatic Encephalopathy | Review

Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy

Authors: Edward Wolfgang Lee, Audrey E. Lee, Sammy Saab, Stephen T. Kee

Published in: Digestive Diseases and Sciences | Issue 9/2020

Login to get access

Abstract

Hepatic Encephalopathy (HE) is a complication of liver disease, consisting of brain dysfunction often due to portosystemic shunting of blood flow in the liver. HE can range from minimal HE, presenting with normal neurological function, to overt HE, with neurological and neuropsychiatric abnormalities. Various clinical grading systems are used to differentiate HE to provide the appropriate treatments. Traditional treatment of HE aims to identify and resolve precipitating factors through targeting hyperammonemia and administering antibiotics or probiotics. While retrograde transvenous obliteration (RTO), including balloon-occluded retrograde transvenous obliteration, coil-assisted retrograde transvenous obliteration or plug-assisted retrograde tranvenous obliteration, is an established procedure to manage gastric varices, little is known about its potential to treat HE. RTO is a procedure to occlude a spontaneous portosystemic shunt, minimizing shunting of portal blood to systemic circulation. Though there is not a large study with HE patients who have undergone RTO; the results appear promising in reducing HE. Side effects, however, should be considered in the treatment of HE such as the transient worsening of portal hypertension and the formation of additional shunts. While additional studies are needed to assess the long-term success, RTO appears to be an effective alternative method to alleviate clinical symptoms of HE when pharmacological therapies and other conservative medical managements have failed.
Literature
1.
go back to reference Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol. 2011;7:222–233. Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol. 2011;7:222–233.
2.
go back to reference Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:480309.PubMedPubMedCentral Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:480309.PubMedPubMedCentral
3.
go back to reference Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515–525.PubMed Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515–525.PubMed
4.
go back to reference McAvoy NC, Hayes PC. Hepatic encephalopathy. Medicine. 2007;35:108–111. McAvoy NC, Hayes PC. Hepatic encephalopathy. Medicine. 2007;35:108–111.
5.
go back to reference Toris GT, Bikis CN, Tsourouflis GS, Theocharis SE. Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Med Sci Monit Int Med J Exp Clin Res. 2011;17:RA53–RA63. Toris GT, Bikis CN, Tsourouflis GS, Theocharis SE. Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Med Sci Monit Int Med J Exp Clin Res. 2011;17:RA53–RA63.
6.
go back to reference Butterworth RF. Hepatic encephalopathy–a serious complication of alcoholic liver disease. Alcohol Res Health J Natl Inst Alcohol Abus Alcohol. 2003;27:143–145. Butterworth RF. Hepatic encephalopathy–a serious complication of alcoholic liver disease. Alcohol Res Health J Natl Inst Alcohol Abus Alcohol. 2003;27:143–145.
7.
go back to reference Perazzo JC, Tallis S, Delfante A, et al. Hepatic encephalopathy: an approach to its multiple pathophysiological features. World J Hepatol. 2012;4:50–65.PubMedPubMedCentral Perazzo JC, Tallis S, Delfante A, et al. Hepatic encephalopathy: an approach to its multiple pathophysiological features. World J Hepatol. 2012;4:50–65.PubMedPubMedCentral
8.
go back to reference Cichoz-Lach H, Michalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J Gastroenterol WJG. 2013;19:26–34.PubMed Cichoz-Lach H, Michalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J Gastroenterol WJG. 2013;19:26–34.PubMed
9.
go back to reference Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–721.PubMed Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–721.PubMed
10.
go back to reference Polson J, Lee WM. American association for the study of liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.PubMed Polson J, Lee WM. American association for the study of liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.PubMed
12.
go back to reference Ortiz M, Cordoba J, Doval E, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther. 2007;26:859–867.PubMed Ortiz M, Cordoba J, Doval E, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther. 2007;26:859–867.PubMed
13.
go back to reference Blei AT, Cordoba J. Practice parameters committee of the American college of G. hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976.PubMed Blei AT, Cordoba J. Practice parameters committee of the American college of G. hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976.PubMed
14.
go back to reference Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology. 2013;58:325–336.PubMed Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology. 2013;58:325–336.PubMed
15.
go back to reference Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.PubMedPubMedCentral Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.PubMedPubMedCentral
16.
go back to reference Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60:715–735.PubMed Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60:715–735.PubMed
17.
go back to reference Zucker DM, Redulla R. Lactulose management of minimal hepatic encephalopathy: a systematic review. Gastroenterol Nurs. 2019;42:84–94.PubMed Zucker DM, Redulla R. Lactulose management of minimal hepatic encephalopathy: a systematic review. Gastroenterol Nurs. 2019;42:84–94.PubMed
18.
go back to reference Wen J, Liu Q, Song J, Tong M, Peng L, Liang H. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Digestion. 2013;87:132–138.PubMed Wen J, Liu Q, Song J, Tong M, Peng L, Liang H. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Digestion. 2013;87:132–138.PubMed
19.
go back to reference Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017;32:1234–1239.PubMed Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017;32:1234–1239.PubMed
20.
go back to reference Maharshi S, Sharma BC, Srivastava S, Jindal A. Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed. Gut. 2015;64:1341–1342.PubMed Maharshi S, Sharma BC, Srivastava S, Jindal A. Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed. Gut. 2015;64:1341–1342.PubMed
21.
go back to reference Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:1250–1257.PubMed Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:1250–1257.PubMed
22.
go back to reference Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–1050.PubMed Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–1050.PubMed
23.
go back to reference Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885–891.PubMed Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885–891.PubMed
24.
go back to reference Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012;27:1329–1335.PubMed Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012;27:1329–1335.PubMed
25.
go back to reference Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081.PubMed Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081.PubMed
26.
go back to reference Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–1463.PubMed Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–1463.PubMed
27.
go back to reference Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol JVIR. 2001;12:327–336.PubMed Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol JVIR. 2001;12:327–336.PubMed
28.
go back to reference Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996;11:51–58.PubMed Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996;11:51–58.PubMed
29.
go back to reference Hirota S, Matsumoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices. Radiology. 1999;211:349–356.PubMed Hirota S, Matsumoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices. Radiology. 1999;211:349–356.PubMed
30.
go back to reference Choi YH, Yoon CJ, Park JH, Chung JW, Kwon JW, Choi GM. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt. Korean J Radiol Off J Korean Radiol Soc. 2003;4:109–116. Choi YH, Yoon CJ, Park JH, Chung JW, Kwon JW, Choi GM. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt. Korean J Radiol Off J Korean Radiol Soc. 2003;4:109–116.
31.
go back to reference Akahoshi T, Hashizume M, Tomikawa M, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol. 2008;23:1702–1709.PubMed Akahoshi T, Hashizume M, Tomikawa M, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol. 2008;23:1702–1709.PubMed
32.
go back to reference Sabri SS, Swee W, Turba UC, et al. Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol JVIR. 2011;22:309–316.PubMed Sabri SS, Swee W, Turba UC, et al. Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. J Vasc Interv Radiol JVIR. 2011;22:309–316.PubMed
33.
go back to reference Gwon DI, Ko GY, Yoon HK, et al. Gastric varices and hepatic encephalopathy: treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration—a primary report. Radiology. 2013;268:281–287.PubMed Gwon DI, Ko GY, Yoon HK, et al. Gastric varices and hepatic encephalopathy: treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration—a primary report. Radiology. 2013;268:281–287.PubMed
34.
go back to reference Lee EW, Saab S, Gomes AS, et al. Coil-assisted retrograde transvenous obliteration (CARTO) for the treatment of portal hypertensive variceal bleeding: preliminary results. Clin Transl Gastroenterol. 2014;5:e61.PubMedPubMedCentral Lee EW, Saab S, Gomes AS, et al. Coil-assisted retrograde transvenous obliteration (CARTO) for the treatment of portal hypertensive variceal bleeding: preliminary results. Clin Transl Gastroenterol. 2014;5:e61.PubMedPubMedCentral
36.
go back to reference Chu HH, Kim M, Kim HC, Lee JH, Jae HJ, Chung JW. Long-term outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices: a comparison of ethanolamine oleate and sodium tetradecyl sulfate. Cardiovasc Interv Radiol. 2018;41:578–586. Chu HH, Kim M, Kim HC, Lee JH, Jae HJ, Chung JW. Long-term outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices: a comparison of ethanolamine oleate and sodium tetradecyl sulfate. Cardiovasc Interv Radiol. 2018;41:578–586.
37.
go back to reference Sabri SS, Saad WE. Balloon-occluded retrograde transvenous obliteration (BRTO): technique and intraprocedural imaging. Semin Interv Radiol. 2011;28:303–313. Sabri SS, Saad WE. Balloon-occluded retrograde transvenous obliteration (BRTO): technique and intraprocedural imaging. Semin Interv Radiol. 2011;28:303–313.
38.
go back to reference Toyonaga A, Oho K. Should B-RTO be the first-line treatment for portosystemic encephalopathy? Intern Med. 2001;40:677–678.PubMed Toyonaga A, Oho K. Should B-RTO be the first-line treatment for portosystemic encephalopathy? Intern Med. 2001;40:677–678.PubMed
39.
go back to reference Baimakhanov Z, Soyama A, Takatsuki M, et al. Effective balloon-occluded retrograde transvenous obliteration of the superior mesenteric vein-inferior vena cava shunt in a patient with hepatic encephalopathy after living donor liver transplantation. Clin J Gastroenterol. 2014;7:342–345.PubMed Baimakhanov Z, Soyama A, Takatsuki M, et al. Effective balloon-occluded retrograde transvenous obliteration of the superior mesenteric vein-inferior vena cava shunt in a patient with hepatic encephalopathy after living donor liver transplantation. Clin J Gastroenterol. 2014;7:342–345.PubMed
40.
go back to reference Ibukuro K, Sugihara T, Tanaka R, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for a direct shunt between the inferior mesenteric vein and the inferior vena cava in a patient with hepatic encephalopathy. J Vasc Interv Radiol JVIR. 2007;18:121–125.PubMed Ibukuro K, Sugihara T, Tanaka R, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for a direct shunt between the inferior mesenteric vein and the inferior vena cava in a patient with hepatic encephalopathy. J Vasc Interv Radiol JVIR. 2007;18:121–125.PubMed
41.
go back to reference Mukund A, Rajesh S, Arora A, Patidar Y, Jain D, Sarin SK. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol JVIR. 2012;23:1200–1206.PubMed Mukund A, Rajesh S, Arora A, Patidar Y, Jain D, Sarin SK. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol JVIR. 2012;23:1200–1206.PubMed
42.
go back to reference Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448–2457.PubMed Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448–2457.PubMed
43.
go back to reference Lee EW, Saab S, Kaldas F, et al. Coil-assisted retrograde transvenous obliteration (CARTO): an alternative treatment option for refractory hepatic encephalopathy. Am J Gastroenterol. 2018;113:1187.PubMed Lee EW, Saab S, Kaldas F, et al. Coil-assisted retrograde transvenous obliteration (CARTO): an alternative treatment option for refractory hepatic encephalopathy. Am J Gastroenterol. 2018;113:1187.PubMed
44.
go back to reference Takada K, Homma H, Takahashi M, et al. A case of successful management of portosystemic shunt with autosomal dominant polycystic kidney disease by balloon-occluded retrograde transvenous obliteration and partial splenic embolization. Eur J Gastroenterol Hepatol. 2001;13:75–78.PubMed Takada K, Homma H, Takahashi M, et al. A case of successful management of portosystemic shunt with autosomal dominant polycystic kidney disease by balloon-occluded retrograde transvenous obliteration and partial splenic embolization. Eur J Gastroenterol Hepatol. 2001;13:75–78.PubMed
45.
go back to reference Gwon DI, Kim YH, Ko GY, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol JVIR. 2015;26:1589–1595.PubMed Gwon DI, Kim YH, Ko GY, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: a prospective multicenter study. J Vasc Interv Radiol JVIR. 2015;26:1589–1595.PubMed
46.
go back to reference Park JK, Cho SK, Kee S, Lee EW. Vascular plug-assisted retrograde transvenous obliteration of portosystemic shunts for refractory hepatic encephalopathy: a case report. Case Rep Radiol. 2014;2014:391420.PubMedPubMedCentral Park JK, Cho SK, Kee S, Lee EW. Vascular plug-assisted retrograde transvenous obliteration of portosystemic shunts for refractory hepatic encephalopathy: a case report. Case Rep Radiol. 2014;2014:391420.PubMedPubMedCentral
47.
go back to reference Saad WE, Sabri SS. Balloon-occluded retrograde transvenous obliteration (BRTO): technical results and outcomes. Semin Interv Radiol. 2011;28:333–338. Saad WE, Sabri SS. Balloon-occluded retrograde transvenous obliteration (BRTO): technical results and outcomes. Semin Interv Radiol. 2011;28:333–338.
48.
go back to reference Kim YH, Kim YH, Kim CS, Kang UR, Kim SH, Kim JH. Comparison of balloon-occluded retrograde transvenous obliteration (BRTO) using ethanolamine oleate (EO), BRTO using sodium tetradecyl sulfate (STS) foam and vascular plug-assisted retrograde transvenous obliteration (PARTO). Cardiovasc Interv Radiol. 2016;39:840–846. Kim YH, Kim YH, Kim CS, Kang UR, Kim SH, Kim JH. Comparison of balloon-occluded retrograde transvenous obliteration (BRTO) using ethanolamine oleate (EO), BRTO using sodium tetradecyl sulfate (STS) foam and vascular plug-assisted retrograde transvenous obliteration (PARTO). Cardiovasc Interv Radiol. 2016;39:840–846.
Metadata
Title
Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy
Authors
Edward Wolfgang Lee
Audrey E. Lee
Sammy Saab
Stephen T. Kee
Publication date
01-09-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06050-7

Other articles of this Issue 9/2020

Digestive Diseases and Sciences 9/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine